By IDSE News Staff
SAN FRANCISCO—In an ongoing trial, bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) (Biktarvy, Gilead) was found to be significantly noninferior to a regimen of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) through 96 weeks of therapy, according to a presentation at IDWeek 2018 (abstract LB4).
Researchers reported the 96-week results from a phase 3 randomized, double-blind trial that is evaluating the safety and efficacy for the treatment of HIV-1 infection